2Chapelsky MC,Thompson K,Miller A.Effect of renal impairment on the pharmacokinetics of rosiglitazone[].Clinical Pharmacology and Therapeutics.1999 被引量：1
3Dicicco R,Allen A,Jorkasky D,et al.Lack of pharmacokinetic drug interaction between rosiglitazone(BRL 49653C)and metformin[].Clinical Pharmacology and Therapeutics.1998 被引量：1
4Shibuya A,Wantanabe M,Fujita Y,et al.An autopsy case of troglitazone-induced fulminant hepatitis[].Diabetes Care.1998 被引量：1
5Inglis AML,Miller AK,Thompson KA,et al.Coadiministration of rosigliatazone and acarbose(A): lack of a clinically relevant pharmacokinetic drug interaction[].Diabetes. 被引量：1
6Digby JE,Montague CT,Sewter CP,et al.Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes[].Diabetes.1998 被引量：1
7Digyb JE,Montague CT,Stewter CP,et al.Thiazolidinediones exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes[].Diabetes.1998 被引量：1
8De-Vos P,Lefebvre AM,Miller SG,et al.Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ[].The Journal of Clinical Investigation.1996 被引量：1
9Buckingham RE,Al-Barazanji KA,Toseland CDN,et al.Peroxisome proliferator-activated receptor agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats[].Diabetes.1998 被引量：1
10Schoonjans K,Martin G,Staels B,et al.Peroxisome proliferator-activated receptors , orphans with ligands and functions[].Current Opinion in Lipidology.1997 被引量：1
